363 related articles for article (PubMed ID: 30421856)
1. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.
Wadden TA; Walsh OA; Berkowitz RI; Chao AM; Alamuddin N; Gruber K; Leonard S; Mugler K; Bakizada Z; Tronieri JS
Obesity (Silver Spring); 2019 Jan; 27(1):75-86. PubMed ID: 30421856
[TBL] [Abstract][Full Text] [Related]
2. Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.
Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS
Obesity (Silver Spring); 2019 Dec; 27(12):2005-2010. PubMed ID: 31746553
[TBL] [Abstract][Full Text] [Related]
3. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.
Tronieri JS; Wadden TA; Walsh O; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Bakizada ZM; Chao AM
Int J Obes (Lond); 2020 Feb; 44(2):353-361. PubMed ID: 30926955
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA; Tronieri JS; Sugimoto D; Lund MT; Auerbach P; Jensen C; Rubino D
Obesity (Silver Spring); 2020 Mar; 28(3):529-536. PubMed ID: 32090517
[TBL] [Abstract][Full Text] [Related]
5. Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg.
Tronieri JS; Wadden TA; Walsh O; Berkowitz RI; Alamuddin N; Chao AM
Behav Res Ther; 2020 Aug; 131():103639. PubMed ID: 32450367
[TBL] [Abstract][Full Text] [Related]
6. Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.
Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS
Clin Obes; 2019 Dec; 9(6):e12340. PubMed ID: 31691531
[TBL] [Abstract][Full Text] [Related]
7. Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
Tronieri JS; Fabricatore AN; Wadden TA; Auerbach P; Endahl L; Sugimoto D; Rubino D
Obes Facts; 2020; 13(6):572-583. PubMed ID: 33197917
[TBL] [Abstract][Full Text] [Related]
8. A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL-IBT Program.
Wadden TA; Tsai AG; Tronieri JS
Obesity (Silver Spring); 2019 Oct; 27(10):1562-1566. PubMed ID: 31544345
[TBL] [Abstract][Full Text] [Related]
9. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
[TBL] [Abstract][Full Text] [Related]
10. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
11. Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.
Capristo E; Panunzi S; De Gaetano A; Raffaelli M; Guidone C; Iaconelli A; L'Abbate L; Birkenfeld AL; Bellantone R; Bornstein SR; Mingrone G
Diabetes Metab; 2018 Jun; 44(3):235-242. PubMed ID: 29398254
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.
Wharton S; Liu A; Pakseresht A; Nørtoft E; Haase CL; Mancini J; Power GS; Vanderlelie S; Christensen RAG
Obesity (Silver Spring); 2019 Jun; 27(6):917-924. PubMed ID: 31062937
[TBL] [Abstract][Full Text] [Related]
16. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
17. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.
Coppin G; Muñoz Tord D; Pool ER; Locatelli L; Achaibou A; Erdemli A; León Pérez L; Wuensch L; Cereghetti D; Golay A; Sander D; Pataky Z
Int J Obes (Lond); 2023 Dec; 47(12):1224-1231. PubMed ID: 37626125
[TBL] [Abstract][Full Text] [Related]
19. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
[TBL] [Abstract][Full Text] [Related]
20. The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
Christou GA; Katsiki N; Kiortsis DN
Curr Vasc Pharmacol; 2016; 14(2):201-7. PubMed ID: 26074046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]